Archived explainer. For the current picture see today's SRPT page.
SAREPTA THERAPEUTICS (SRPT) is up +13.10% in the latest session. Our newswire has captured 1 story on SRPT across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Sarepta Therapeutics (SRPT) surged 13.10% to $22.01 in a single session driven by a mix of positive earnings, leadership changes, and analyst upgrades. The stock is on track for its best week in five months as investors look ahead to late-2026 clinical data from mid-stage trials for two muscle diseases. Analyst activity and unusual options activity have also contributed to the sharp price movement.
Sarepta Therapeutics announced Q2 adjusted earnings per share of $0.64, exceeding the estimated $0.26. Revenue for the quarter was reported at $401.3 million, surpassing the expected $364.34 million. The company also announced the appointment of Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram. This leadership change has been interpreted by some as a strategic shift that could benefit the company’s long-term prospects.
Analyst coverage has been mixed but trending positive. Piper Sandler maintained a Neutral rating but lowered its price target to $20. In contrast, Wolfe Research upgraded the stock to Outperform with a $27 price target. These developments, combined with anticipation for late-2026 clinical data, have drawn attention from both institutional and retail investors.
The stock opened at $19.45 and reached an intraday high of $22.59 at 1:35 PM ET before settling at $22.14. The session saw 5.4 million shares traded, which is 1.7 times the 3-month daily average. Options activity was skewed toward calls, with a total premium of $16.7 million, compared to $0 in put premiums. The largest single print was $7.8 million. On August 27, the stock printed 34 fresh 52-week highs, indicating strong momentum.
Investors should monitor the company’s late-2026 clinical data releases for facioscapulohumeral muscular dystrophy and myotonic dystrophy. These results could significantly influence the stock’s trajectory. Additionally, the breadth of analyst coverage and any further upgrades or downgrades will be important to track in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
More on SRPT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier SRPT move explainers: 2026-09-10 · 2026-09-09 · 2026-09-08 · 2026-08-28 · 2026-08-27